Osthole attenuates pulmonary arterial hypertension in monocrotaline‑treated rats

Li,Yeli; Wang,Yingwan; Li,Yiqi; Qian,Zhiqiang; Zhu,Ling; Yang,Danli

doi:10.3892/mmr.2017.6876

Osthole attenuates pulmonary arterial hypertension in monocrotaline‑treated rats

Authors:
- Yeli Li
- Yingwan Wang
- Yiqi Li
- Zhiqiang Qian
- Ling Zhu
- Danli Yang
View Affiliations

Affiliations: Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou 563003, P.R. China, Department of Pharmacology, Zunyi Medical University, Zhuhai, Guangdong 519041, P.R. China
Published online on: June 29, 2017 https://doi.org/10.3892/mmr.2017.6876
Pages: 2823-2829

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pulmonary arterial hypertension (PAH) is an insidious and progressive disease that is triggered by various cardiopulmonary diseases. Inflammation has an important role in the progression of PAH. Osthole (Ost) is a coumarin that has clear anti‑inflammatory properties. The present study aimed to investigate the effects of Ost on PAH, and to explore the mechanism underlying this effect. Using the monocrotaline (MCT)‑induced PAH rat model, the effects of Ost on PAH were investigated. Rats were subcutaneously administered a single dose of MCT (50 mg/kg) to establish the PAH model, followed by daily treatment with Ost (10 or 20 mg/kg) by gavage for 28 days. The mean pulmonary arterial pressure (mPAP) was measured and histological analysis was performed. The results demonstrated that Ost significantly decreased mPAP, and reduced thickening of the pulmonary artery, compared with in rats in the MCT group. To further determine whether the effects of Ost on MCT‑induced PAH were associated with inflammatory responses, the nuclear factor‑κB (NF‑κB) p65 signaling pathway was investigated by western blot analysis. The results demonstrated that Ost increased inhibition of the NF‑κB p65 signaling pathway. In conclusion, the results of the present study demonstrate that Ost may suppress the progression of MCT‑induced PAH in rats, which may be, at least partially, mediated through modulation of the NF‑κB p65 signaling pathway.

View Figures

View References

1	Archer SL, Weir EK and Wilkins MR: Basic science of pulmonary arterial hypertension for clinicians: New concepts and experimental therapies. Circulation. 121:2045–2066. 2010. View Article : Google Scholar : PubMed/NCBI
2	Nakata TM, Tanaka R, Yoshiyuki R, Fukayama T, Goya S and Fukushima R: Effects of single drug and combined short-term administration of sildenafil, pimobendan, and nicorandil on right ventricular function in rats with monocrotaline-induced pulmonary hypertension. J Cardiovasc Pharmacol. 65:640–648. 2015. View Article : Google Scholar : PubMed/NCBI
3	Rabinovitch M, Guignabert C, Humbert M and Nicolls MR: Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res. 115:165–175. 2014. View Article : Google Scholar : PubMed/NCBI
4	Ahmed LA, Obaid AA, Zaki HF and Agha AM: Role of oxidative stress, inflammation, nitric oxide and transforming growth factor-beta in the protective effect of diosgenin in monocrotaline-induced pulmonary hypertension in rats. Eur J Pharmacol. 740:379–387. 2014. View Article : Google Scholar : PubMed/NCBI
5	White RJ and Morrell NW: Understanding the low penetrance of bone morphogenetic protein receptor 2 gene mutations: Another needle in the haystack. Circulation. 126:1818–1820. 2012. View Article : Google Scholar : PubMed/NCBI
6	Sutendra G, Dromparis P, Bonnet S, Haromy A, McMurtry MS, Bleackley RC and Michelakis ED: Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension. J Mol Med (Berl). 89:771–783. 2011. View Article : Google Scholar : PubMed/NCBI
7	Hassoun PM, Mouthon L, Barberà JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, et al: Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 54:(1 Suppl). S10–S19. 2009. View Article : Google Scholar : PubMed/NCBI
8	Sen R and Baltimore D: Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell. 47:921–928. 1986. View Article : Google Scholar : PubMed/NCBI
9	Kimura H, Okada O, Tanabe N, Tanaka Y, Terai M, Takiguchi Y, Masuda M, Nakajima N, Hiroshima K, Inadera H, et al: Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 164:319–324. 2001. View Article : Google Scholar : PubMed/NCBI
10	Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M and Fabel H: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 342:1866–1870. 2000. View Article : Google Scholar : PubMed/NCBI
11	Wilkins MR, Ali O, Bradlow W, Wharton J, Taegtmeyer A, Rhodes CJ, Ghofrani HA, Howard L, Nihoyannopoulos P, Mohiaddin RH, et al: Simvastatin as a treatment for pulmonary hypertension trial. Am J Resp Crit Care Med. 181:1106–1113. 2010. View Article : Google Scholar : PubMed/NCBI
12	Galié N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 353:2148–2157. 2005. View Article : Google Scholar : PubMed/NCBI
13	Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE and McGoon MD: An evaluation of long term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 142:448–456. 2012. View Article : Google Scholar : PubMed/NCBI
14	Zhang ZR, Leung WN, Cheung HY and Chan CW: Osthole: A review on its bioactivities, pharmacological properties, and potential as alternative medicine. Evid Based Complement Alternat Med. 2015:9196162015. View Article : Google Scholar : PubMed/NCBI
15	Liao PC, Chien SC, Ho CL, Wang EI, Lee SC, Kuo YH, Jeyashoke N, Chen J, Dong WC, Chao LK and Hua KF: Osthole regulates inflammatory mediator expression through modulating NF-κB, mitogen-activated protein kinases, protein kinase C, and reactive oxygen species. J Agric Food Chem. 58:10445–10451. 2010. View Article : Google Scholar : PubMed/NCBI
16	Zhang XP, Chen XM, Cui QH and Tian JZ: Studies on pharmacological activity and mechanism of osthole. China Licensed Pharmacist. 11:28–32. 2013.
17	You L, Feng S, An R and Wang X: Osthole: A promising lead compound for drug discovery from a traditional Chinese medicine (TCM). Nat Prod Commun. 4:297–302. 2009.PubMed/NCBI
18	Wang R, Kong J, Wang D, Lien LL and Lien EJ: A survey of Chinese herbal ingredients with liver protection activities. Chin Med. 2:52007. View Article : Google Scholar : PubMed/NCBI
19	Li Z, Ji H, Song X, Hu J, Han N and Chen N: Osthole attenuates the development of carrageenan-induced lung inflammation in rats. Int Immunopharmacol. 20:33–36. 2014. View Article : Google Scholar : PubMed/NCBI
20	Zheng Y, Lu M, Ma L, Zhang S, Qiu M and Ma X: Osthole ameliorates renal ischemia-reperfusion injury by inhibiting inflammatory response. Urol Int. 91:350–356. 2013. View Article : Google Scholar : PubMed/NCBI
21	O'Blenes SB, Fischer S, McIntyre B, Keshavjee S and Rabinovitch M: Hemodynamic unloading leads to regression of pulmonary vascular disease in rats. J Thorac Cardiovasc Surg. 121:279–289. 2001. View Article : Google Scholar : PubMed/NCBI
22	Nogueira-Ferreira R, Vitorino R, Ferreira R and Henriques-Coelho T: Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. Pulm Pharmacol Ther. 35:8–16. 2015. View Article : Google Scholar : PubMed/NCBI
23	Campian ME, Hardziyenka M, Michel MC and Tan HL: How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol. 373:391–400. 2006. View Article : Google Scholar : PubMed/NCBI
24	Nishimura T, Faul JL, Berry GJ, Veve I, Pearl RG and Kao PN: 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med. 163:498–502. 2001. View Article : Google Scholar : PubMed/NCBI
25	Rey M, Hess P and Clozel M: Monocrotaline-induced pulmonary hypertension in Wistar rats. Curr Protoc Pharmacol Chapter. 5:Unit 5.56. 2009. View Article : Google Scholar
26	Liu C, Fang C, Cao G, Liu K, Wang B, Wan Z, Li S and Wu S: Ethyl pyruvate ameliorates monocrotaline-induced pulmonary arterial hypertension in rats. J Cardiovasc Pharmacol. 64:7–15. 2014. View Article : Google Scholar : PubMed/NCBI
27	Wang X, Wang Y, Rong S and Ma H: Early treatment with hepatocyte growth factor improves pulmonary artery and right ventricular remodeling in rats with pulmonary artery hypertension by modulating cytokines expression. Zhonghua Jie He He Hu Xi Za Zhi. 37:427–432. 2014.(In Chinese). PubMed/NCBI
28	Liu ZQ, Liu B, Yu L, Wang XQ, Wang J and Liu HM: Effect of simvastatin on expression of cyclooxygenase-2 in a rat model of pulmonary artery hypertension. Chin Heart J. 21:625–628. 2009.
29	Lee TL, Yeh J, Friedman J, Yan B, Yang X, Yeh NT, Van Waes C and Chen Z: A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer. 122:1987–1998. 2008. View Article : Google Scholar : PubMed/NCBI
30	Hoffmann A, Levchenko A, Scott ML and Baltimore D: The IkappaB-NF-kappa B signaling module: Temporal control and selective gene activation. Science. 298:1241–1245. 2002. View Article : Google Scholar : PubMed/NCBI
31	Ogawa A, Firth AL, Yao W, Rubin LJ and Yuan JX: Prednisolone inhibits PDGF-induced nuclear translocation of NF-kappaB in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 295:L648–L657. 2008. View Article : Google Scholar : PubMed/NCBI
32	Wang XL, Shang X, Cui Y, Zhao X, Zhang Y and Xie ML: Osthole inhibits inflammatory cytokine release through PPARα/γ-mediated mechanisms in LPS-stimulated 3T3-L1 adipocytes. Immunopharmacol Immunotoxicol. 37:185–192. 2015. View Article : Google Scholar : PubMed/NCBI